Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-16

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Create a living biobank of PDOs from Stage I-III lung cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Generation of Lung Tumor Organoids From Patients Undergoing Diagnostic Bronchoscopy

NCT06239584

Generation of Lung Cancer Organoids

RECRUITING NA

To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer

NCT04342286

Kidney Cancer

COMPLETED

Prospective Primary Human Lungcancer Organoids to Predict Treatment Response

NCT04859166

Lung Cancer

COMPLETED

Lung Cancer Organoids and Patient Derived Tumor Xenografts

NCT05092009

Lung Cancer

RECRUITING

Specimen Banking From Patients With Lung Cancer

NCT01585675

Lung Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Creation a living biobank of PDOs from Stage I-IV lung cancer patients (n=50). We selected enrollment of at least 50 patients so that they can be risk stratified based on lung tumor type, staging and we plan to store these PDOs in biobank for future experiments. For each patient, tumor specimens will be collected at time of their surgery. No specific therapeutic intervention or treatment is provided as part of this study.

1. Establishment and culture of PDOs from lung cancer tumor specimens. PDOs will be biobanked for future experiments.
2. Lung organoids and CTCs will also be cultured and used to study baseline tumor characteristics using histology, immunohistochemistry, atomic force measurements; as well as, oncogenic signaling pathways and proteomic profile of lung organoids and CTCs derived from lung cancer patients (n\>50).
3. Patient demographic information and data to be collected using a patient survey data sheet with treatment and survival history collected at pre-defined time period per the protocol schedule.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lung Tumor Resection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
* Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
* Any clinical stage of lung cancer
* Adult patients ≥18 years of age
* Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history